SpainSpain

Gearing up for the flu season

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu vaccines. To be built in Granada, the production plant will have an annual capacity of 10 million doses of vaccine against seasonal flu and 30 million against pandemic flu. At the end of September, Alentia also said it had signed an agreement with Novartis Vaccines & Diagnostics for the transfer and granting of a licence of use for Novartis vaccine production technology. The construction costs for the new plant are estimated at around €92m.

SpainSpain

04.11.2010

Seville – Genetrix S.L. and the Botín Foundation will channel a 6m over the next three years into the new company Axontherapix SL. The public-private partnership will seek to develop an effective therapy for Parkinson’s Disease....

SpainSpain

03.11.2010

Pamplona – With a record-setting Biospain this year, the Spanish biotech industry has underpinned its role as a premier player in the sector in southern Europe. More than 1,400 business representatives flocked to Pamplona, where...

SpainSpain

28.09.2010

Bilbao – Spanish Progenika Biopharma S.A has gained the green light for sale of its LPLchip in Europe. The DNA chip, which has achieved the CE mark, detects approximately 120 mutations in the lipoprotein lipase (LPL) gene and...

SpainSpain

22.09.2010

Madrid – Responding to the current debate surrounding the reactome array investigation, Manuel Ferrer from the Institute of Catalysis and Petrochemistry in Madrid told EuroBiotechNews his team would “clarify all the scientific...

SpainSpain

09.09.2010

Madrid – When Chinese Premier Wen Jiabao met his Spanish colleague Jose Luis Rodriguez Zapatero on August 31st, he talked about the Mediterranean country’s role as an important economic partner for China, and said cooperation...

SpainSpain

04.08.2010

Madrid/Braunschweig - Spanish and German scientists who last year reported a groundbreaking technology that is able to identify the whole set of biochemical reactions in bacteria or cells, together with the enzymes involved, have...

SpainSpain

11.07.2010

Barcelona – While the cash-strapped Spanish government is being stripped of its AAA grade investment rating, one of the giants of the country’s life science industry is on a spending spree. Grifols, a producer of plasma protein...

SpainSpain

09.07.2010

Barcelona/Nantes – Biomarker-specialist TcLand Expression in Nantes has found an ally in the Vall d’Hebron University Hospital Research Institute (HVIR) in Barcelona. The French company and the Spanish clinic will work together...

SpainSpain

08.06.2010

Barcelona/Triangle Park – Spanish producer of plasma protein therapies Grifols is to acquire US public biopharmaceutical company Talecris, in a deal worth approximately $3.4 billion (EUR2.8 billion). The merger will improve...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/2/article/gearing-up-for-the-flu-season.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products